Objective: Increased circulating levels of lipopolysaccharide (LPS) have been demonstrated in HIV-1-infected progressors. We investigated the effect of antiretroviral therapy (ART) interruptions on plasma LPS levels.
Introduction
During established HIV-1 infection, an increase in plasma bacterial lipopolysaccharide (LPS) levels has been proposed to reflect microbial translocation from the gut serving as a potential inflammatory stimulus accelerating disease pathogenesis [1] . The level and effect of circulating LPS can be modulated by LPS-binding protein (LBP) [2] , soluble CD14 (sCD14) [3] [4] [5] , naturally occurring antibodies to the LPS core oligosaccharide [endotoxin-core antibodies (EndoCAb)] [6, 7] and plasma gelsolin (which can bind actin and LPS) [8] [9] [10] [11] [12] . The interplay between antiretroviral therapy (ART) interruption-mediated viremic episodes and changes in plasma levels of LPS and its host-derived ligands remains unknown and is the subject of this study.
Patients and methods

Participants
Cryopreserved plasma from 26 uninfected and 51 HIVpositive patients was analyzed. Ten out of the 51 HIVpositive participants were viremic ART-naive [median, 25th-75th interquartile range (IQR) plasma HIV-1 RNA (viral load)¼19601 copies/ml (11545, 69954); median (IQR) CD4 cell count ¼ 273.5 cells/ml (191. 25, 347) ] and 41 of 51 HIV-positive participants were chronically suppressed patients participating in a parent study [recruitment characteristics: age !18 years, presence of ART (three or more drugs), CD4 cell count >400 cells/ml with a history of nadir CD4 cell count !100 cells/ml, and viral load <50 copies/ml with a >6 months history of <500 copies/ml] and followed under continuous therapy (n ¼ 20) or repeated therapy interruptions (n ¼ 21) before undergoing an open-ended therapy interruption. Patient demographics for the parent study are described in our prior publications [13, 14] .
Samples from uninfected and viremic ART-naive HIVpositive patients were analyzed at a single visit, whereas available samples from the parent study were analyzed as follows: at baseline (viral load <50 copies/ml on ART, n ¼ 41), on continuous ART for a 40-week follow-up (n ¼ 16), during a 6-week therapy interruption (n ¼ 21)
, and during open-ended therapy interruption: after patients reached viral set point (average viral load of the first three consecutive measurements of viral load with <0.5 log variation, n ¼ 21) and at the last available viremic time point of the open-ended therapy interruption (n ¼ 9).
Informed consent was obtained according to the Human Experimentation Guidelines of the US Department of
Health and Human Services and of the authors' institutions. The study protocol was approved by the Institutional Review Boards of the Wistar Institute and Philadelphia FIGHT.
Lipopolysaccharide levels and immune activation LPS levels were determined in duplicate by the limulus amebocyte assay according to the manufacturer's protocol (Cambrex Bioscience, Walkersville, Maryland, USA) in plasma samples diluted 1/100 (dilution determined by product inhibition test) with endotoxin-free water and heated to 708C for 10 min to inactivate plasma proteins. Plasma levels of sCD14 (R&D, Minneapolis, Minnesota, USA), LBP (Cell Sciences, Canton, Massachusetts, USA), IgM EndoCAb (Cell Sciences), and IFN-a (PBL Biomedical Laboratories, Piscataway, New Jersey, USA) were determined by enzyme-linked immunosorbent assay (ELISA) as per manufacturer's specifications. Measurements were run in duplicate on a kinetic absorbance reader at 450 nm (Rainbow Reader; SLT-Lab Instruments, Grodig/Salzburg, Austria). Lower limits for LPS, sCD14, LBP, EndoCAb and IFN-a were 0.1 EU/ml, 250 pg/ml, 781.25 pg/ml, 0.054 MMU/ml and 12.5 pg/ml, respectively. Plasma levels of gelsolin were determined by immunoblotting using monoclonal antihuman gelsolin antibody (G4896; Sigma, St Louis, Missouri, USA) as described [11] . Whole blood flow cytometry was used for assessment of T-cell activation (CD8 þ /CD38 þ , CD8 þ /HLA-DR þ and CD3 þ / CD95 þ ) as described [15] .
Statistical analysis
Data are presented as medians with 25th-75th IQR in parenthesis. Variable distributions were analyzed for normality using the Shapiro-Wilk W test (P > 0.05). Depending on data distribution, between groups comparisons were performed by t-test or the Wilcoxon/Kruskal-Wallis test (rank sums), whereas between time points comparisons were performed using nonparametric Wilcoxon sign-rank test or paired t-tests. Associations between variables were assessed using Spearman or pairwise correlation tests. All statistical tests were performed using JMP4 (SAS Institute, Cary, North Carolina, USA).
Results
Increased plasma lipopolysaccharide levels observed only after long-term HIV-1 replication Initial cross-sectional analysis showed that ART suppressed HIV-1-positive patients had lower LPS levels 370 AIDS 2009, Vol 23 No 3 compared with uninfected participants (P < 0.0001), whereas ART-naive viremic patients had higher LPS levels compared with ART-suppressed HIV-1-positive patients (P ¼ 0.0003) ( Fig. 1a ).
Longitudinal analysis showed no change in LPS levels during continuous ART, as well as during therapy interruptions of less than 12 weeks, including analysis during a 6-week therapy interruption [median (IQR) viral load ¼ 10 745 copies/ml (2527, 61 874), Fig. 1b ] and during open-ended therapy interruption when viral set point was reached [median (IQR) duration ¼ 9 weeks (8, 12) ; median (IQR) viral load ¼ 11 067 copies/ml (2851, 26 259)]. In contrast, steady-state viremia for more than 12 weeks resulted in significantly increased LPS levels (P ¼ 0.0171, Fig. 1c (12, 35); median (IQR) viral load ¼ 43 748 copies/ml (23 192 , 101 044)] compared with levels at start of the open-ended therapy interruption (viral load <50 copies/ ml). This differential effect of less than 12 versus more than 12 weeks of viral replication on LPS levels was observed despite a lack of significant difference in viral load. The impact of prolonged viremia was also supported by the longitudinal change of LPS in patients followed over sequential 6 week to more than 12 weeks therapy interruptions (P ¼ 0.0009, n ¼ 7, Fig. 1d ) and by crosssectional analysis showing higher LPS levels in patients with steady-state viremia for more than 12 weeks therapy interruption compared with uninfected participants (P < 0.0001) or ART-suppressed HIV-1-positive patients (P ¼ 0.031).
Lack of association between onset of immune activation and plasma lipopolysaccharide levels
In agreement with previous studies, we observed a significant rise in the frequency of CD3 þ /CD95 þ (P ¼ 0.0022, n ¼ 21), CD8 þ /CD38 þ (P < 0.0001, n ¼ 20, Fig. 1e ) and CD8 þ /HLA-DR þ (P ¼ 0.001, n ¼ 20) T cells concurrent with the onset of viral replication during the 6-week therapy interruption. Change in the frequency of activated T cells after therapy interruption was observed despite lack of changes in LPS levels (Fig. 1b) . No correlation between LPS levels and T-cell activation or plasma levels of IFN-a following therapy interruption was observed at any time point analyzed.
Binding of lipopolysaccharide by endotoxin-core antibodies and sCD14 during therapy interruption-mediated viral rebound To investigate potential reasons for a lack of change in LPS levels after short-term viremia, plasma levels of LPSbinding molecules (EndoCAb, sCD14, LBP, gelsolin) were measured on the same samples.
A constitutive role for EndoCAb in modulating LPS levels was supported by a negative correlation between LPS and EndoCAb levels in uninfected participants (correlation ¼ À0.430, P ¼ 0.0282). Activation of an effective LPS clearance response by circulating EndoCAb during less than 12 weeks therapy interruption was suggested by a negative association between viral load at week 6 of therapy interruption (correlation ¼ À0.502, P ¼ 0.0204) and the change of EndoCAb (DEndoCAb) from start to end of the 6-week therapy interruption ( Fig. 2a) . A negative association between viral load and LPS levels at week 6 of therapy interruption (Spearman's Rho ¼ À0.612, P ¼ 0.0152) was also observed ( Fig. 2a ) concurrent with a lack of rise in LPS (Fig. 1) . A strong negative association between DEndoCAb and DLPS (correlation ¼ À0.851, P ¼ 0.0073) was present from time on therapy to a subsequent steady-state viremic time point during less than 12 weeks therapy interruption (Fig. 2b) , whereas no correlation between EndoCAb and 372 AIDS 2009, Vol 23 No 3 LPS was observed after more than 12 weeks therapy interruption.
In contrast to EndoCAb, sCD14 showed a positive association with LPS ( Fig. 1f ). In addition, sCD14 showed changes similar to those observed for LPS, such as higher levels in steady-state viremic patients for more than 12 weeks therapy interruption (P ¼ 0.02) or ART-naive patients (P ¼ 0.0006) compared with uninfected participants and in ART-naive patients (P < 0.0001) compared with ART-suppressed HIV-1-positive patients (data not shown). Levels of sCD14 did not change during continuous ART or a 6-week therapy interruption, but increased during long-term therapy interruption for more than 12 weeks compared with levels during ART (P < 0.0001), further suggesting sCD14 to be a correlate to LPS levels. A negative correlation between DsCD14 and DEndoCAb (correlation ¼ À0.896, P ¼ 0.0025) during a 6-week therapy interruption was also observed.
Unexpectedly, no difference among groups or change during viremia was demonstrated for LBP or gelsolin, beside lower levels of LBP in steady-state viremic patients after more than 12 weeks therapy interruption compared with uninfected participants (P ¼ 0.01).
Discussion
We found different effects of viral replication on LPS plasma levels possibly dependent on the duration of the viremic episode and the degree of plasma LPS clearance by its ligands over time. No association between plasma LPS levels and the onset of immune activation during therapy interruption-associated viral replication was observed.
Increased EndoCAb IgM levels are common in conditions of chronic microbial translocation in the presence of functional B-cell responses [16] , whereas acute microbial translocation coincides with lower levels of EndoCAb [7, 17, 18] . Decreases in EndoCAb levels observed in our study during viral replication of less than 12 weeks suggest that clearance of LPS from the circulation during short-term viremia is mediated by EndoCAb. A rise in LPS levels during long-term viremia of more than 12 weeks is likely attributed to EndoCAb saturation by excess of LPS or to inadequate B-cell function [19] .
Consistent with previous studies showing increased levels of sCD14 in trauma [20] , sepsis [21, 22] , autoimmune diseases [23, 24] , and HIV-1 infection [1, 25, 26] , we observed a rise of sCD14 plasma levels in the presence of viral replication. In contrast to EndoCAb, no negative association with LPS was found, suggesting an inactivating role for sCD14 in the presence of LPS. In contrast to EndoCAb or sCD14, no changes in plasma levels of LBP and gelsolin were observed at any time point. These findings could be explained by differences in affinity, production, or clearance of these other LPS-binding molecules, or perhaps by the low molar ratio of LPS to these relatively abundant ligands.
Brenchley et al. [1] reported decreased LPS levels in the presence of ART and a positive association between immune activation and plasma LPS levels in chronically HIV-infected patients and in patients with AIDS. We not only confirmed their finding in patients with HIV viremia, but also observed lower LPS levels in suppressed patients compared with uninfected participants. This last counterintuitive finding may potentially reflect independent effect of ART on LPS levels or gut flora. Use of antibiotic prophylaxis by our suppressed patients could have contributed to this finding, and this type of information should be collected in targeted future studies to address this possibility. In addition to effective inactivation of LPS effects by EndoCAb in the short term, the observed lack of association between LPS levels and initial changes in immune activation following therapy interruption may be attributable to characteristics of our cohort such as lack of progression to AIDS, prior exposure to ART resulting in control of immune activation during suppression, or limited exposure to viral replication. Importantly, our data do not exclude the fact that T-cell activation during therapy interruption-mediated viremia may be affected by microbial translocation in addition to direct HIV-1 effects, as this study did not address measurement of other microbial products or their direct effects on T cells [27, 28] or both.
Taken together, our data indicate that control of plasma microbial product translocation is only transiently maintained in the face of de-novo viral replication following therapy interruption and is dependent on the duration of the viremic episode and EndoCAb levels. This finding may help explain the lack of a positive association between LPS levels and viral load observed by others and us. The mechanism and capacity of LPS clearance achievable during therapy interruption following immune reconstitution remain to be further elucidated. This study was established before the SRA was initiated, and no support from it enabled any of the work presented in this manuscript. More than 7 years ago, M.J.DiN. served as a paid consultant to Biogen that was developing aerosolized rhGSN for the treatment of lung disease in patients with cystic fibrosis. He has more recently advised Critical Biologics Corporation (which has acquired the rights to rhGSN) regarding potential diagnostic and therapeutic uses of pGSN on an informal basis and without reimbursement. He is currently an employee of Merck Research Laboratories, which has no past or present ties to the development of gelsolin. 
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